Skip to main content
Top
Published in:

01-06-2025 | Obesity | Review article

DPP-IV and FAS inhibitory peptides: therapeutic alternative against diabesity

Authors: Ma. Fabiola León-Galván, Daniela Sarahi Medina-Rojas

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2025

Login to get access

Abstract

Diabesity is a modern epidemic that indicates a strong association between obesity and diabetes. Key enzymes have been identified in the development and progression of both diseases, DPP-IV in glucose uptake and FAS in fatty acid synthesis. In both cases, the molecular mechanisms of how each one acts separately have been described, and which are the key inhibitory drugs and molecules for each one. However, although it is known that there is an association between both clinically and molecularly, the mechanism has not been elucidated; therefore, this review focuses on proposing a mechanism of convergence of DPP-IV and FAS in diabesity, and the possible mode of action in which bioactive peptides obtained from plant and animal sources can inhibit these two enzymes in a similar way as drugs do.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
DPP-IV and FAS inhibitory peptides: therapeutic alternative against diabesity
Authors
Ma. Fabiola León-Galván
Daniela Sarahi Medina-Rojas
Publication date
01-06-2025
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2025
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-025-01613-9

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more